Cosmeceuticals
This article was originally published in The Rose Sheet
Executive Summary
The market for cosmeceuticals sold across mass, department, specialty and other retailers in the U.S. was estimated to be around $500 mil.-$600 mil. in 2005, according to Karen Young, president of marketing firm The Young Group. Exec presented during the Strategic Research Institute-sponsored Cosmeceuticals meeting in New York City June 8-9. In her presentation "Getting Your Brand Into the Channels That Count," Young noted the Internet remains an excellent means to attract new customers to a brand, and 80% of consumers regularly or occasionally purchase products online...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.